Skip to Content

Clinical Trials & Research

Clinical trials are research studies that have been carefully designed to answer questions about new ways to prevent cancer, treat cancer, and manage side effects of treatment.

The Hall-Perrine Cancer Center participates in national clinical trials through the National Cancer Institute (NCI) and national and international studies through the pharmaceutical industry. These types of clinical trials are leading to major breakthroughs in cancer treatment in our own community.

Through the Iowa-Wide Oncology Research Coalition (I-WORC), Oncology Associates at Mercy Medical Center actively participates in more than 45 clinical trials at any given time. This allows a great number of patients access to trials based on the cancer and stage of cancer.

For more information about clinical trials, call Lynn Arens, BS, CCRP at (319) 363-2690 or e-mail larens@mercycare.org.

Current Clinical Trials Available at Hall-Perrine Cancer Center

Brain

ALLIANCE A221101:

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma. Learn more.

ALLIANCE N1174:

Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme. Learn more.

Breast

ECOG-ACRIN E2112:

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer. Learn more.

ALLIANCE A011106:

ALTernate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study. Learn more.

EISAI/ACCRU RU011201I:

A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. Learn more.

CTSU S1202:

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer. Learn more.

CTSU S1007:

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer. Learn more.

CTSU S1207:

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy. Learn more.

Gastrointestinal

CTSU S0820:

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES). Learn more.

CTSU RTOG-1010:

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma. Learn more.

ECOG-ACRIN E2211:

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors. Learn more. 

ECOG-ACRIN E7208:

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B) in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy. Learn more.

ALLIANCE CALGB-80702:

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer. Learn more.

Genitourinary

CTSU S0931: EVEREST:

EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study. Learn more.

CTSU S1216:

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer. Learn more.

Gynecological

More information coming soon!

Head and Neck

More information coming soon!

Hematologic

ECOG-ACRIN E1411:

Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR). Learn more.

ECOG-ACRIN E1412:

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. Learn more.

ECOG-ACRIN E2905:

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia. Learn more.

ALLIANCE CALGB 50904:

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients with Untreated Follicular Lymphoma. Learn more.

ALLIANCE A041202:

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL). Learn more.

Lung

CTSU S0819:

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Learn more.

ECOG-ACRIN E2511:

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer. Learn more.

ECOG-ACRIN E4512:

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. Learn more.

ECOG-ACRIN E5508:

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC. Learn more.

ALLIANCE A081105:

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). Learn more.

ALLIANCE A151216:

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Learn more.

Melanoma

More information coming soon!

Other

ALLIANCE N107C:

A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease. Learn more.

ECOG-ACRIN E1Z11:

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). Learn more.

HELSINN TIDE-13-14:

An international, multicenter, prospective, cohort observational study to assess the incidence of chemotherapy-induced diarrhea in colorectal and breast cancer patients.

MERCK V212-011:

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011). Learn more.

CTSU SCUSF-0806:

Phase II placebo-controlled trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin). Learn more.

ALLIANCE A021202:

Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND# 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors. Learn more.

ALLIANCE A221102:

Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias. Learn more.

Symptom Management/Cancer Control

More information coming soon!

Thyroid

More information coming soon!

Please note: Participation in clinical trials require that participants meet very specific eligibility criteria. Please check with your physician to see if you may be eligible. This website is periodically updated to list studies currently available. Please speak with your doctor to inquire if a particular clinical trial is currently enrolling patients.

American Cancer Society

Clinical Trials Matching Service is a free, confidential program that helps patients, their families and healthcare professionals find cancer clinical trials most appropriate to a specific patient, taking their medical and personal history in consideration. For more information, call 1-800-303-5691 or visit http://cancer.org/clinicaltrials.

National Cancer Institute

The National Cancer Institute (NCI) offers a clinical trials search feature along with patient education on clinical trials. For more information, go to http://www.cancer.gov/clinicaltrials.

Courageous Stories

Brita LoynachanBrita's heart and drive of a champion helped her overcome a battle against breast cancer.

Follow Brita's Story

To discuss treatments call (319) 365-HOPE (4673)